KLF6 and Hepatic fibrosis: miR-148a targets Kruppel-like factor 6 (KLF6) to suppress pro-inflammatory macrophages and promote anti-inflammatory macrophages by inhibiting the STAT3 pathway, which could be exploited as a potential therapeutic target for liver fibrosis [58].